Biofrontera Announces FDA Has Approved Co.'s sNDA To Increase Maximally Approved Dosage From One To Three Tubes Of Ameluz Topical Gel Per Treatment
Portfolio Pulse from Benzinga Newsdesk
Biofrontera has received FDA approval for its supplemental New Drug Application (sNDA) to increase the maximum approved dosage of Ameluz topical gel from one to three tubes per treatment. This approval could potentially enhance the product's marketability and sales.
October 07, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biofrontera's FDA approval for increasing the dosage of Ameluz gel from one to three tubes per treatment could lead to increased sales and market presence.
The FDA approval allows Biofrontera to market Ameluz gel with a higher dosage, which can lead to increased usage and sales. This regulatory milestone is significant for the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100